Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CDC7 inhibitor TQB3824

An orally bioavailable inhibitor of cell division cycle 7 (CDC7) kinase, with potential antineoplastic activity. Upon oral administration, CDC7 inhibitor TQB3824 targets, binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays a key role in DNA replication and DNA damage response by binding to and phosphorylating serine (Ser)-40 and 53 of minichromosome maintenance complex component 2 (MCM2).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CDC7 kinase inhibitor TQB3824
cell division cycle 7 kinase inhibitor TQB3824
Code name:TQB 3824
TQB-3824
TQB3824
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search